title: Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.
abstract: OBJECTIVE
  To evaluate whether the presence of mucinous differentiation influences histopathologic findings, stage distribution, or rate of recurrence among women with grade 1, endometrioid type, endometrial carcinoma.
  
  
  METHODS
  This was a retrospective cohort study of all patients with grade 1, endometrioid type, endometrial carcinoma between January 2005 and December 2012. Patients were separated by the presence or absence of mucinous differentiation and then compared.
  
  
  RESULTS
  Of 655 patients, mucinous differentiation was present in 137 (20.9%) and absent in 518 (79.1%) patients. Compared to the group without mucinous differentiation, the group containing mucinous differentiation was older at diagnosis (mean: 61.1 vs. 58.5 years, OR, 95% CI; 1.03, 1.01-1.05) and more likely to have myometrial invasion (61.3% vs. 51.5%, OR, 95% CI; 1.49, 1.01-2.19). Additional histopathologic findings including: tumor size, cervical stromal invasion, adnexal involvement, LVI and/or the presence of positive lymph nodes were similar between groups. Mucinous differentiation did not affect stage distribution, as most patients were stage 1A (85.4% vs. 86.3%). The median PFS for the entire group has yet to be reached. The mean PFS for the entire study sample was 94.7 months. There was no difference in mean PFS when comparing the group with mucinous differentiation to the group without mucinous differentiation (98 vs. 93.4 months, p=0.07).
  
  
  CONCLUSIONS
  In the setting of grade 1, endometrioid type, endometrial carcinoma, mucinous differentiation is more common in older patients and is associated with an increased likelihood of myometrial invasion. However, stage distribution and risk of recurrence are not affected.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Worley
authors.affiliation: Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States.
authors.forename: Michelle
authors.initials: M
authors.lastname: Davis
authors.affiliation: Harvard Medical School, Boston, MA, United States.
authors.forename: Saba H
authors.initials: SH
authors.lastname: Berhie
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Muto
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States.
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Feltmate
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States.
authors.forename: Ross S
authors.initials: RS
authors.lastname: Berkowitz
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States.
authors.forename: Neil S
authors.initials: NS
authors.lastname: Horowitz
authors.affiliation: Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, United States. Electronic address: Susana_campos@dfci.harvard.edu.
authors.forename: Susana M
authors.initials: SM
authors.lastname: Campos
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000473:pathology; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000453:epidemiology* / Q000473:pathology*; D002454:Cell Differentiation; D015331:Cohort Studies; D016889:Endometrial Neoplasms / Q000453:epidemiology* / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D012306:Risk
keywords: Endometrial cancer; Mucinous differentiation; Well differentiated